Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ингибиторы ангиотензинпревращающего фермента: значимы ли имеющиеся различия для клиники?
Ингибиторы ангиотензинпревращающего фермента: значимы ли имеющиеся различия для клиники?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Крупные клинические испытания продемонстрировали, что ИАПФ обладают важными кардиопротективными свойствами. Результаты исследований демонстрируют эффективность терапии ИАПФ при АГ, ХСН, ИБС. Исследования SMILE показали кратко- и долгосрочные положительные результаты раннего начала (<24 ч) терапии зофеноприлом у больных с ОИМ. Эти результаты были подтверждены в подгруппах больных высокого риска, в том числе у лиц с гипертонией и сахарным диабетом, что позволяет рекомендовать зофеноприл для широкого клинического применения у лиц с АГ и ИБС, в том числе после перенесенного острого инфаркта миокарда. Зофеноприл имеет лучший профиль безопасности, чем ряд других препаратов. Так в исследовании ZAAMIS оценка антиишемических эффектов зофеноприла производится путем прямого сравнения двух ИАПФ с различными фармакологическими профилями.
Ключевые слова: артериальная гипертензия, ишемическая болезнь сердца, острый инфаркт миокарда, факторы риска, ингибиторы ангиотензинпревращающего фермента, зофеноприл
Key words: arterial hypertension, coronary heart disease, acute myocardial infarction, risk factors, angiotensin-converting enzyme inhibitors, zofenopril.
Ключевые слова: артериальная гипертензия, ишемическая болезнь сердца, острый инфаркт миокарда, факторы риска, ингибиторы ангиотензинпревращающего фермента, зофеноприл
________________________________________________
Key words: arterial hypertension, coronary heart disease, acute myocardial infarction, risk factors, angiotensin-converting enzyme inhibitors, zofenopril.
Полный текст
Список литературы
1. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5 (9): 1965–77.
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl 2007; 2: 13–8.
3. de Nigris F, Armiento F, Somma P et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme ingibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and angiogenesis in apolipoprotein E knockout mice. Intern J Cardiol 2001; 81: 107–15.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press Suppl 2007; 2: 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press Suppl 2007; 2: 19–24.
6. Malacco E, Piazza S, Omboni S; on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd., 1998; с. 37–44.
9. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
10. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
11. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1–8.
12. Borghi С, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute nyocardial infarction. Am J Cardiol 1996; 78: 317–22.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
15. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7–14.
16. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
17. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
18. Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag 2008; 4 (3): 665–71.
19. Borghi C, Cicero AF, Bacchelli S et al. Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol 2009; 23 (5): 641–8.
2. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl 2007; 2: 13–8.
3. de Nigris F, Armiento F, Somma P et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme ingibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and angiogenesis in apolipoprotein E knockout mice. Intern J Cardiol 2001; 81: 107–15.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press Suppl 2007; 2: 7–12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press Suppl 2007; 2: 19–24.
6. Malacco E, Piazza S, Omboni S; on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
8. Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd., 1998; с. 37–44.
9. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373–81.
10. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
11. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1–8.
12. Borghi С, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute nyocardial infarction. Am J Cardiol 1996; 78: 317–22.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371–584.
14. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470–7.
15. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7–14.
16. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631–47.
17. Borghi С, Bacchelli S, Esposti DD et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665–72.
18. Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag 2008; 4 (3): 665–71.
19. Borghi C, Cicero AF, Bacchelli S et al. Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol 2009; 23 (5): 641–8.
Авторы
А.А.Кириченко
Кафедра терапии РМАПО, Москва
Department of Therapy, Russian Medical Academy of Postgraduate Education
Кафедра терапии РМАПО, Москва
________________________________________________
Department of Therapy, Russian Medical Academy of Postgraduate Education
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.